In Vivo and In Vitro Services to Advance Your Drug Discovery

TD2’s integrated suite of preclinical services provides our clients with data that drives the development of clinical strategy. From the discovery stage to NDA strategy, we offer our clients advanced solutions to move their programs forward.

Our comprehensive service offerings utilized to rapidly move your treatments to the clinic include DMPK/ADME, in vitro and in vivo pharmacology, expert study design and execution. Your in vivo pharmacology studies are run in our AAALAC-accredited rodent facility with the highest regard for animal welfare. All studies are conducted with a commitment to meeting the high-quality standards you expect, and each offering is customizable to meet your unique development needs. With expert drug development insight and strategy and skilled project management, TD2 is your partner for an efficient path to the clinic.

Preclinical Models and Services


Models and Services

TD2’s service offering is consistently expanding and currently includes:

In vivo and In vitro Characterization

Therapeutic Evaluation:

Tumor Models Trusted IO Models

Tumor Models

Trusted IO Models

At TD2, we are dedicated to providing you with the most comprehensive preclinical immuno-oncology studies possible. Our experienced team offers a broad range of human and murine tumor models that allow for the planning and execution of studies in solid or hematologic malignancies.

Our syngeneic tumor models are fully characterized for gene expression, TIL baseline populations, and response to common immune checkpoint inhibitors (ICI), allowing for rapid, trusted study outcomes. These syngeneic cell lines can also be combined with our wide range of humanized immune checkpoint inhibitor mouse models to evaluate your ICI treatment. When syngeneic mouse systems are not applicable for your drug, we can employ the use of humanized mice either by engrafting with human PBMCs or other effector cells or utilizing sourced CD34+ humanized mice.

TD2’s vast experience in Adoptive Cell Transfer Therapy studies in both solid and hematologic tumors is unmatched in the industry. We have the expertise to provide you with the most accurate and reliable data possible, ensuring the success of your drug development program.

Cell Therapy Models +

Syngeneic Models +

Humanized Immune Checkpoint Inhibitor Mouse Models +

Tumor Models

Specialized Animal Models

Regardless of the development question, TD2 has the specialized model you need to move your drug forward. Clients have access to humanized models, induction models, as well as specialty surgical and orthotopic models. Since we specialize in all areas of oncology and work diligently to understand your therapeutic’s mechanism of action and match that with clinical development strategies, we are constantly working to validate new model systems that represent areas of unmet medical need.

Glioblastoma PDX Models

We have more than 60 first-presentation and recurrent Primary (PDX) Glioblastoma Models that include:

  • MOA-Based Filters using selections driven by your drug’s specific mechanism of action and subsequent interrogation
  • Diverse tissue types including fixed tissue for analysis of novel markers
  • Assessment of tumor progression as single agents and in combination with standard therapies via orthotopic primary tumor models
  • Well-established protocols that ensure an extremely high post-surgery survival rate
  • Data-rich and highly characterized models with standard of care

Specialized Glioblastoma Models +

Multiple Myeloma Models

Our Multiple Myeloma Transgenic Mouse Model is proven to improve multiple myeloma efficacy studies with more than 60 agents from Vk-Myc, a genetically engineered, clinically predictive mouse model from Dr. Leif Bersagel’s lab housed at the Mayo Clinic.

Fibrosis Models

Inflammation is a common factor driving many diseases, including both oncology and fibrosis. Models of fibrosis can be very useful in multiple areas, including understanding drug effects on the tumor microenvironment. Our fibrosis induction liver models include DEN, CCl4, choline-deficient high-fat diet in addition to the bleomycin lung injury model.

Tumor Models Specialized Animal Models

In Vitro Pharmacology

In Vitro Pharmacology

In vitro tools to guide your preclinical therapy.

With TD2’s vast set of in vitro preclinical tools, you can explore drug effects on tumor cells, immune cells, and tumor/effector cell potentiation for earlier guidance on efficacy. Utilizing our in-house Tecan D300 digital dispenser, TD2 can ensure precise delivery of test agents giving rapid and confident data sets. When you partner with an oncology CRO like TD2, you will have access to more than 400 proof-of-concept tumor cell lines – all well-characterized – making the transition to in vivo studies seamless.

In our In Vitro Pharmacology Laboratory, we execute assays that can:

  • Define potency on viability in a panel of cell lines
  • Identify sensitivity and resistance profiles
  • Shape in vivo proof of concept study design
  • Determine combination interaction outcomes with immune effector cells
  • Assess combination interaction with standard of care agents (Synergy studies)
  • Determine optimal drug sequencing

In Vivo Pharmacology

Support for your preclinical goals.

With access to our expansive collection of human and murine tumor cell-line based models representing all of the major and many rare histologies, TD2 can assist its clients with expert selection of relevant tumor xenograft or syngeneic models tailored to your development questions in a way that will rapidly drive development of your therapy. Our in vivo efficacy studies are designed to identify, streamline, and optimize development strategies for your oncology therapeutic – including endpoints of tumor growth inhibition, tumor growth delay, imaging endpoints and biomarker analysis – and give you direction on your path to the clinic.

Additional support in in vivo preclinical services includes:


WHigh-tech, multi-modal AMI 1000 optimal imaging designed for powerful bioluminescence, fluorescence and X-ray

Toxicology Assessments

Non-GLP toxicology assessments including dose range finding, pharmacokinetic analysis, CBC and blood chemistries, and highly sophisticated histopathology services used to glean early toxicity insights

Data Collection

Accurate data collection and reporting using StudyLog®, our electronic data collection software that enables reliable data collection and faster analysis

Expert Project Management

Expert project management for efficient study execution and reliable data delivery

View Current Vivarium Monitoring Report

In Vivo Pharmacology

Additional Resources

Validated Tumor Cell Lines

Epigenetic-Based Combinatorial Therapy is Synergistic in KRAS/LKB1 Mutant Non-Small Cell Lung Cancers

Integrating PDX GBM In Vivo Models with Patient History and Whole Exome Sequencing: Advancing Relevance and Precision in Preclinical Studies

Flow cytometry evaluation of cell cycle arrest in A549 human non-small cell lung cancer cells and tumors following treatment with cell cycle inhibitors: A multifaceted approach to targeting cancer

Immunophenotyping Pig Immune Cells by Flow Cytometry: A Powerful Tool for Pharmacology and Toxicology Studies

Flow Cytometry Application in Water Microbiology: Testing Bacterial Content in Water

Flow Cytometry Processing and Analysis of Tumor Specimens: Testing Viability and Staining Post Shipping

Flow Cytometry Based Assessment of Innate Immune Function Using Phagocytosis and Reactive Oxygen Species Measurement

Measurement of Cytokine mRNA Expression by Flow Cytometry Using the Branched DNA Technology

10-Color Flow Cytometry Panels for the Evaluation of T Cell Subsets Such as TH Subsets, T Cell Activation, and T Regulatory Cells for Application in Clinical Trials

The Advantages of Fluorescent Barcoding of Human Cells Using Flow Cytometry for High Throughput Testing With an Application For Human Clinical Trials

The Activation Profiling of Stat in Human Whole Blood Samples By Flow Cytometry With an Application for Human Clinical Trials

Design and Validation of a Model of a Receptor Occupancy Assay for a New Immunotherapy in Human Whole Blood Specimens

The Importance of Metabolic and Proteomic Analyses in Identifying Treatment Pathways for Cancer Patients

Advancing Preclinical Cancer Research Through Metabolomics: Key Strategies for Biomarker Identification and Drug-Target Analysis in Immuno-Oncology

E-Book: Using the Diet Induced Obese Mouse Model for Modern Cancer Research

A Dual-specific Inhibitor of Rock/Aurk, RR-1752, for Primary Myelofibrosis

Inhibition of HDAC3 Induces BRCAness and Potent Synergy with PARP Inhibition in Neuroendocrine Prostate and Small Cell Lung Cancers

Selective HDAC6 Inhibition By GB-1101 Revokes Tumor Immune Privilege and Synergizes with Immune Checkpoint Therapies to Induce Tumor Regressions

SITC 2023 Poster: Antitumor and metabolomic evaluation of immune checkpoint inhibition in diet-induced obese mice

Orthotopic vs. Subcutaneous: Unpacking the Strengths and Limitations of Tumor Model Implantation Sites

Unveiling the Potential: 5 Ways DIO Mice Enhance Immuno-Oncology Discoveries

Genetically Engineered Humanized Mouse Models: A Critical Tool for Studying Immunotherapy Drugs

Diet-Induced Obesity Tumor Models for Cancer Studies

Metabolomics Sample Data Analysis Report

Preclinical, Posters and Publications

Metabolomics Sample Data Analysis Report

Antitumor and metabolomic evaluation of immune checkpoint inhibition in diet-induced obese mice

Leading the way in defining a new Immunotherapy Response Score (IRS) to predict checkpoint inhibitor benefit

The Dynamic Trial Design

Preclinical, Webinars

The Dynamic Trial Design

Checkpoint inhibitors: the gut microbiome’s role in anti-tumor response

Inhibition of HDAC3 Induces BRCAness and Potent Synergy with PARP Inhibition in Neuroendocrine Prostate and Small Cell Lung Cancers

Selective HDAC6 Inhibition By GB-1101 Revokes Tumor Immune Privilege and Synergizes with Immune Checkpoint Therapies to…

Exploring the Effects of Microbiome in Precision Oncology Therapeutic Development

Many Drugs Don’t Move Past Phase I. Will Yours?


6 Signs You Need a New CRO for Your Preclinical Research


Have questions about how TD2 can assist with your preclinical needs?

We’re an oncology CRO that keeps the bottom line in mind – getting your treatment to those who need it most in the safest, most efficient way possible.